Actinic Keratosis Market, by Treatment (Medication, Surgical Procedure, Photodynamic Therapy, Combination Therapies, By End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022

Description

Actinic Keratosis (AK) is the most common pre-cancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun. Actinic Keratosis is also known as solar keratosis. Actinic keratosis forms like a patch on the skin. The patches usually appear on areas of your body that are often exposed to the sun, such as your face, hands and arms, ears, scalp and legs. Sometimes actinic keratosis can turn into squamous cell skin cancer. For this reason, the lesions are often called pre-cancer. Patches are not life-threatening. But if patches are found and treated early, they do not have the chance to develop into skin cancer. Actinic Keratosis can affect:

People with pale skin, blonde or red hair, and blue, green, or gray eyes
People with darker skin, hair, and eyes who have been exposed to UV rays without protection
Older adults
People with suppressed immune systems (due to chemotherapy, AIDS, organ transplant, or other causes)
People with rare conditions that make the skin very sensitive to UV rays, such as albinism or xeroderma pigmentosum (XP)

Market Dynamics

Increasing number of drug approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive growth of the global actinic keratosis market during the forecast period. For instance, In November 2017, Perrigo Company plc, an Ireland based healthcare company, had announced that the company had received tentative approval from the U.S. Food and Drug Administration (FDA) for the generic version of Picato Gel (ingenol mebutate) 0.05%. It is indicated for the topical treatment of actinic keratosis.

High incidence rate of skin cancer is expected to drive growth of the global actinic keratosis market. For instance, according to American Academy of Dermatology Association 2022, Skin cancer is the most common cancer in the U.S. It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. It is estimated that the overall incidence of basal cell carcinoma (BCC) increased by 145% between 1976-1984 and between 2000-2010, and the overall incidence of squamous cell carcinoma (SCC) increased 263% over that same period.

Key features of the study:

This report provides an in-depth analysis of global actinic keratosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global actinic keratosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals Inc., Biofrontera AG., Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global actinic keratosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global actinic keratosis

Detailed Segmentation:

Global Actinic Keratosis Market, By Treatment:
- Medication
- Surgical Procedure
  - Chemical peel
  - Cryosurgery
  - Curettage and desiccation
  - Laser surgery
- Photodynamic Therapy
- Combination Therapies
  - Cryosurgery and PDT
  - Cryosurgery and a topical treatment
  - Topical treatments and PD
Global Actinic Keratosis Market, By End User:
- Hospitals & Specialty Clinics
- Homecare
Global Actinic Keratosis Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Almirall, S.A*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Bausch Health Companies Inc.
- Perrigo Company plc
- Sun Pharmaceutical Industries Ltd.
- Hill Dermaceuticals, Inc.
- Spear Pharmaceuticals
- Tolmar Pharmaceuticals, Inc.
- Biofrontera AG
- Cipher Pharmaceuticals Inc.
- Vidac
- Athenex, Inc.
- 3M
- Mayne Pharma Group Limited

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1006

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Industry Trends
PEST Analysis
Pipeline Analysis
Key Development
Regulatory Scenario
Epidemiology
Overview of Treatment Guidelines for Actinic Keratosis

4. Global Actinic Keratosis Market- Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Supply and Demand Analysis

5. Global Actinic Keratosis Market, By Treatment, 2017-2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Surgical Procedure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Chemical peel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Cryosurgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Photodynamic Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Cryosurgery and PDT
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Cryosurgery and a topical treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Topical treatments and PD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global Actinic Keratosis Market, By End User, 2017-2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospitals and Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Homecare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global Actinic Keratosis Market, By Region, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa

8. Competitive Landscape

Company Profiles
- Almirall,S.A.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Bausch Health Companies Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Perrigo Company plc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Sun Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Hill Dermaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Spear Pharmaceuticals
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Tolmar Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Biofrontera AG
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Cipher Pharmaceuticals Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Vidac
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Athenex, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- 3M
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Mayne Pharma Group Limited
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Analyst Views

9. Section

References
Research Methodology
About Us and Sales Contact

Actinic Keratosis Market, by Treatment (Medication, Surgical Procedure, Photodynamic Therapy, Combination Therapies, By End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030